Increased anti-EBV activity after CTL infusion. Immediately before and at 6, 8, and 16 weeks after the first infusion of CTL, cytotoxic T-cell lines were generated from the PBMC of a patient with relapsed Hodgkin's disease by culturing the cells with autologous LCLs (see Methods). The data, presented as percentage of⁵¹Cr release from autologous LCLs at an effector:target ratio of 20:1, demonstrate a maximum 28-fold rise in anti-EBV activity following CTL infusion (▪). There was no significant increase in MHC-unrestricted activated killer activity as demonstrated by there being no increase in the percentage of ⁵¹Cr release from HLA-mismatched LCL targets (□).